China launches mission to get asteroid samples
China on Thursday launched its first space mission to retrieve samples from a nearby asteroid and conduct research back home, the Xinhua state news agency reported.
A successful completion of the mission could make China, a fast-growing space power, the third nation to get hold of the pristine asteroid rocks.
The mission began with a Long March-3B rocket carrying the Tianwen-2 probe blasting off from the Xichang launch site in southwestern Sichuan province at 1:31 a.m. local time (1731 GMT/UTC).
It took 18 minutes for the Tianwen-2 spacecraft to enter a transfer orbit for asteroid 2016HO3, the China National Space Administration (CNSA) said, according to Xinhua.
"The spacecraft unfolded its solar panels smoothly, and the CNSA declared the launch a success," the news agency wrote.
Tianwen-2 is scheduled to arrive at the asteroid in July 2026 and shoot a capsule packed with rocks back to Earth for a landing in November 2027.
The asteroid was discovered in 2016 by scientists in Hawaii and is roughly 40 to 100 metres (130-330 feet) in diameter and revolves relatively close to Earth.
The Tianmen-2 spacecraft is also tasked with exploring the comet 311P, according to the country's space agency.
China has swiftly made its mark with its expanding space program.
In the past few years, it has poured billions of dollars into its space program to achieve what President Xi Jinping describes as the country's "space dream."
China already has its own space station, and in recent years, it has managed to send robots to the far side of the moon. It is now planning to send humans to the lunar surface by 2030.
Edited by: Farah Bahgat
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
High Growth Tech Stocks in Asia Featuring 3 Promising Picks
Amid escalating geopolitical tensions and trade-related concerns, Asian markets have shown resilience, with China's recent trade agreements providing a glimmer of optimism despite ongoing deflationary pressures. In this dynamic environment, identifying high-growth tech stocks in Asia involves evaluating companies that can leverage technological innovation and strategic positioning to navigate economic challenges and capitalize on emerging opportunities. Name Revenue Growth Earnings Growth Growth Rating Suzhou TFC Optical Communication 29.78% 30.32% ★★★★★★ Shengyi Electronics 22.99% 35.16% ★★★★★★ Fositek 26.71% 33.90% ★★★★★★ Shanghai Huace Navigation Technology 24.44% 23.48% ★★★★★★ Range Intelligent Computing Technology Group 27.31% 28.63% ★★★★★★ eWeLLLtd 24.95% 24.40% ★★★★★★ PharmaResearch 24.47% 25.73% ★★★★★★ Nanya New Material TechnologyLtd 22.72% 63.29% ★★★★★★ Global Security Experts 20.56% 28.04% ★★★★★★ JNTC 54.24% 87.93% ★★★★★★ Click here to see the full list of 488 stocks from our Asian High Growth Tech and AI Stocks screener. We're going to check out a few of the best picks from our screener tool. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Celltrion, Inc. is a biopharmaceutical company focused on developing, producing, and selling therapeutic proteins for oncology treatments with a market capitalization of ₩35.78 trillion. Operations: The company primarily generates revenue from its biopharmaceutical segment, which accounts for ₩6.18 trillion. It also earns from chemical drugs, contributing ₩523.71 million to its total revenue. Celltrion, a key player in the biotech sector, is making significant strides with its FDA-approved biosimilar YUFLYMA®, enhancing patient access through strategic price adjustments and expanded interchangeable designations. The company's commitment to innovation is further underscored by a robust 27.2% forecasted annual earnings growth and an aggressive share repurchase program, signaling strong future prospects. Moreover, recent clinical trials highlight potential safety advantages of their products over competitors', positioning Celltrion favorably within the high-growth biotechnology landscape in Asia. Click to explore a detailed breakdown of our findings in Celltrion's health report. Assess Celltrion's past performance with our detailed historical performance reports. Simply Wall St Growth Rating: ★★★★★☆ Overview: China Ruyi Holdings Limited is an investment holding company involved in content production and online streaming across Mainland China, Hong Kong, Europe, and other international markets, with a market capitalization of approximately HK$33.99 billion. Operations: China Ruyi Holdings Limited primarily generates revenue through its online streaming and gaming businesses, which contribute CN¥3.51 billion, followed by content production at CN¥127.04 million. Amid a challenging fiscal year, China Ruyi Holdings has demonstrated resilience with strategic financial maneuvers, including a substantial fixed-income offering of HKD 2.341 billion and aggressive private placements aimed at bolstering its capital structure. Despite reporting a net loss of CNY 190.53 million for 2024, contrasting sharply with the previous year's profit, the company is poised for recovery with projected revenue growth at an impressive rate of 27.4% annually. This outlook is supported by recent corporate actions such as share repurchases and convertible bond issues, underscoring management's commitment to navigating through volatile markets while maintaining focus on long-term growth strategies in high-tech sectors across Asia. Click here and access our complete health analysis report to understand the dynamics of China Ruyi Holdings. Gain insights into China Ruyi Holdings' past trends and performance with our Past report. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Innovent Biologics, Inc. is a biopharmaceutical company focused on the research and development of antibody and protein medicine products across China, the United States, and internationally, with a market cap of HK$132.62 billion. Operations: The company generates revenue primarily from its biotechnology segment, amounting to CN¥9.42 billion. Innovent Biologics has recently made significant strides in the biopharmaceutical field, particularly with its innovative cancer treatments. The company's recent regulatory successes include multiple Breakthrough Therapy Designations (BTDs) and Fast Track Designations (FTDs) from both U.S. and Chinese health authorities for its novel PD-1/IL-2a-bias bispecific antibody fusion protein, IBI363. These designations, which aim to expedite the development and review process for promising drugs, highlight Innovent's commitment to addressing critical unmet medical needs in oncology. Moreover, the acceptance of New Drug Applications (NDAs) by China's NMPA for other advanced therapies underscores Innovent's potential to impact global health outcomes significantly. Get an in-depth perspective on Innovent Biologics' performance by reading our health report here. Learn about Innovent Biologics' historical performance. Embark on your investment journey to our 488 Asian High Growth Tech and AI Stocks selection here. Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools. Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include KOSE:A068270 SEHK:136 and SEHK:1801. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
2 hours ago
- Yahoo
Clover Initiates Phase I Clinical Trial for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates
-- Potential First-in-Class Respiratory Combination Vaccine Candidates SCB-1022 (RSV + hMPV) and SCB-1033 (RSV + hMPV + PIV3) Enter the Clinical Trial Stage -- SHANGHAI, June 17, 2025 /PRNewswire/ -- Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, today announced that enrollment of the first participants has been completed in a Phase I clinical trial evaluating SCB-1022 (RSV+hMPV) and SCB-1033 (RSV+hMPV+PIV3) respiratory combination vaccine candidates based on prefusion-stabilized F (PreF)-Trimer subunit vaccine antigens utilizing Clover's Trimer-Tag vaccine technology platform. "We are pleased to announce the Phase I clinical trial initiation of our potential first-in-class combination vaccine candidates SCB-1022 (RSV+hMPV) and SCB-1033 (RSV+hMPV+PIV3), further demonstrating the differentiated value of our validated Trimer-Tag platform," said Joshua Liang, Chief Executive Officer & Board Director of Clover. "While currently approved protein-based RSV vaccines are safe & effective, critical gaps persist globally, including the inability to prevent significant respiratory disease burden caused by other viruses related to RSV such as human metapneumovirus (hMPV) and parainfluenza virus type 3 (PIV3). Thus, we look forward to the clinical trial results for our respiratory combination vaccine candidates in order to maximize our impact on public health globally." In October 2024, Clover announced Phase I results in 70 older adults (60-85 years) for Clover's non-adjuvanted RSV PreF vaccine candidate (SCB-1019) compared head-to-head to GSK's AS01E-adjuvanted RSV vaccine (AREXVY), and results indicated a potential best-in-class combined immunogenicity & tolerability profile of SCB-1019. These results supported the further development and evaluation of SCB-1019 in combination with the PreF-Trimer antigens for hMPV and PIV3, which are also utilizing the Trimer-Tag platform. The ongoing Phase I trial for Clover's combination vaccine candidates is enrolling up to 192 older adults (60-85 years), and the participants will be randomized to receive either SCB-1022 (RSV+hMPV), SCB-1033 (RSV+hMPV+PIV3) or SCB-1019 (RSV) comparator. The study will assess safety, reactogenicity and immunogenicity. About Clover Clover Biopharmaceuticals is a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world. With integrated research and development, manufacturing and commercial capabilities as well as strong partnerships with organizations globally, Clover has a diverse pipeline of candidates that have the potential to meaningfully reduce the burden of vaccine-preventable diseases—and to make more diseases preventable. Clover Forward-looking Statements This press release contains certain forward-looking statements and information relating to us and our subsidiaries that are based on the beliefs of our management as well as assumptions made by and information currently available to our management. When used, the words "aim," "anticipate," "believe," "could," "estimate," "expect," "going forward," "intend," "may," "might," "ought to," "plan," "potential," "predict," "project," "seek," "should," "will," "would" and the negative of these words and other similar expressions, as they relate to us or our management, are intended to identify forward-looking statements. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. We give no assurance that these expectations and assumptions will prove to have been correct. Because forward-looking statements relate to the future, they are participant to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. We caution you therefore against placing undue reliance on any of these forward-looking statements. Any forward-looking statement made by us in this document speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time. View original content: SOURCE Clover Biopharma Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
Chinese Automakers Gain Ground in Global EV Race as Other World Leaders Risk Falling Behind
New ICCT report reveals China's growing advantage in EV sales as BYD edges past Tesla in global BEV sales for the first time WASHINGTON, June 17, 2025 /PRNewswire/ -- The International Council on Clean Transportation (ICCT) today released its third annual Global Automaker Rating, showing that China-based automakers are building significant leads in the zero-emission vehicle (ZEV) market as the country now accounts for over 11 million electric vehicles sold annually – more than half of global EV sales. Chinese manufacturers occupied the top 5 positions in ZEV class coverage and 5 of 6 top positions for EV sales share, with companies like Geely and SAIC already reaching 50% EV sales share, meeting their 2025 targets a year ahead of schedule. Among the report's other key findings, BYD exceeded Tesla in global battery electric vehicle (BEV) sales for the first time in 2024, with a 25% increase in BEV sales and 47% increase in combined BEV and plug-in hybrid electric vehicle sales compared to 2023. Both companies remain in the "Leaders" category. "Our assessment revealed widespread improvement in BEV technology performance across the industry," said Zifei Yang, ICCT's Global Passenger Vehicle Lead and principal author. "The vast majority of automakers demonstrated enhancements in energy consumption, charging speed, and driving range. GM and Honda made significant advancements by introducing high-performance models to their previously limited offerings." In a significant milestone, India-based Tata Motors became the first major automaker to transition from the "laggard" group to the "transitioner" group by introducing new EV models and ramping up battery recycling efforts. The report also highlights the increasing importance of manufacturing emissions through a newly introduced green steel metric, with automakers like Mercedes-Benz, BMW, and Volkswagen scoring well on sustainable procurement efforts. "Investors increasingly recognize that automakers embracing the EV transition aren't just preparing for regulatory compliance—they're positioning themselves for long-term market leadership," said Michael Kodransky, Senior Director at Ceres. "As China-based automakers expand globally, other leading global manufacturers face urgent pressure to accelerate their own transitions," said Drew Kodjak, ICCT President and CEO. "For the wider global auto industry, this is no longer just about meeting future goals – it's about remaining competitive today in a market that's charging up." See full report View original content to download multimedia: SOURCE The International Council on Clean Transportation (ICCT) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
